Carrie Smith Cox
Carrie Smith Cox's purchase track record
Carrie Smith Cox has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/13/2022 | RNAC | $150K | +63.4% | +14.3% | +6.4% |
| 12/3/2021 | RNAC | $51K | -44.3% | -69.5% | -9.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Solventum Featured in Yahoo’s Overrated and Profitable Stock Lists. Yahoo highlighted Solventum in two recent articles. In one piece it was listed among stocks that may be overvalued, while the other article named it a profitable long‑term option. The coverage may influence how investors view the company’s valuation and growth prospects. The stock remains near the middle of its 52‑week range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session. Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cardinal Health Hits Record Highs as Sector Strength Continues. Cardinal Health's stock has reached record highs, outperforming the broader market as the healthcare sector shows strong momentum. In corporate news, Senior Vice President Shane Abeyratne has joined the Customer Experience Advisory Board of Level AI. Meanwhile, market observers are looking ahead to the company's upcoming Q1 2027 earnings report and its position as a defensive option in the current economic environment.
Transaction History
| TXN | ▲ Buy | Option Exercise | 4,306 | $474K | 5/13/2026 | View on chart |
| TXN | ▲ Buy | Option Exercise | 4,532 | $473K | 5/13/2026 | View on chart |
| TXN | ▼ Sell | Open Market | 8,393 | $2.6M | 5/13/2026 | View on chart |
| TXN | ▼ Sell | Open Market | 445 | $137K | 5/13/2026 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 4,916 | $0 | 4/30/2026 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 6,336 | $0 | 3/27/2026 | View on chart |
| TXN | ▲ Buy | Grant | 525 | $0 | 1/29/2026 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 5,148 | $0 | 5/13/2025 | View on chart |
| TXN | ▲ Buy | Grant | 614 | $0 | 1/27/2025 | View on chart |
| RNAC | ▲ Buy | Grant | 2,600 | $0 | 1/2/2025 | View on chart |
| TXN | ▲ Buy | Grant | 686 | $0 | 1/25/2024 | View on chart |
| RNAC | ▲ Buy | Grant | 178,000 | $0 | 1/2/2024 | View on chart |
| TXN | ▲ Buy | Option Exercise | 9,990 | $529K | 7/31/2023 | View on chart |
| TXN | ▲ Buy | Option Exercise | 6,065 | $481K | 7/31/2023 | View on chart |
| TXN | ▼ Sell | Open Market | 16,055 | $2.9M | 7/31/2023 | View on chart |
| TXN | ▲ Buy | Grant | 574 | $0 | 1/26/2023 | View on chart |
| CAH | ▲ Buy | Grant | 2,308 | $0 | 11/9/2022 | View on chart |
| RNAC | ▲ Buy | Open Market | 130,000 | $150K | 6/13/2022 | View on chart |
| TXN | ▲ Buy | Grant | 572 | $0 | 1/27/2022 | View on chart |
| RNAC | ▲ Buy | Open Market | 17,200 | $51K | 12/3/2021 | View on chart |
| CAH | ▲ Buy | Grant | 3,709 | $0 | 11/11/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
TXN Announces Q3 Earnings Preview and Q4 2026 Dividend
Texas Instruments will report Q3 earnings next week, with analysts noting key metrics that could influence expectations. The board also declared a quarterly dividend for Q4 2026, adding to shareholder value. These developments keep the stock in focus for investors monitoring earnings performance and dividend policy.
TXN Announces Q3 Earnings Preview and Q4 2026 Dividend. Texas Instruments will report Q3 earnings next week, with analysts noting key metrics that could influence expectations. The board also declared a quarterly dividend for Q4 2026, adding to shareholder value. These developments keep the stock in focus for investors monitoring earnings performance and dividend policy.